• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Doctors
    • Information
      • Service invoicing
      • Service invoicing for pathologists
    • Clinical trials
      • Lung Cancer Study Group
      • General information
  • Patients
    • General information
      • Driver mutations in lung cancer
      • New immunotherapeutic therapeutic approaches
      • Second Opinion service
      • Molecular Diagnostics
      • New therapeutic approaches from genomic research
    • Clinical trials
      • Lung Cancer Study Group
      • General information
      • What is a clinical trial?
      • Participation in a trial
    • Find doctors nearby
  • The Network
    • Aims
    • Funding
    • Our team
    • Publications
    • Related links
  • Driver mutations
  • Diagnostics
  • Hybrid-capture
  • Fast-track analysis for first-line treatment
Select Page

ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

Michels SYF, Scheel AH, Wündisch T, Heuckmann JM, Menon R, Puesken M, Kobe C, Pasternack H, Heydt C, Scheffler M, Fischer R, Schultheis AM, Merkelbach-Bruse S, Heukamp L, Büttner R, Wolf J

Journal: NPJ Precis Oncology
published: 2017 Mar 20

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress